Ocular Therapeutix Inc OCUL

NAS: OCUL | ISIN: US67576A1007 14/11/2024

9,920 USD (-6,42%)

(-6,42%) 14/11/2024

Grafiek Ocular Therapeutix Inc

Grafiek Ocular Therapeutix Inc

1 dag1d -6,42%
1 week1w -10,63%
1 maand1m -3,03%
3 maanden3m 18,52%
6 maanden6m 57,71%
1 jaar1j 340,89%
5 jaar5j 254,29%

Ocular Therapeutix Inc in het nieuws

Toon enkel gratis nieuws

19 februari 2024 · AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis · Persbericht

31 oktober 2023 · AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery · Persbericht

13 april 2022 · AffaMed Therapeutics Announces New Drug Approval for DEXTENZA in Macau for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery · Persbericht

Profiel Ocular Therapeutix Inc

Fabricage van farmaceutische preparaten

Farmaceutische producten: Andere

Gezondheidstechnologie

Website: www.ocutx.com

Hoofdzetel: Bedford, Massachusetts Verenigde Staten

CEO: Antony Mattessich

Werknemers: 274

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe